Rovi reported 13.2% revenue growth in H1 2026
Total revenue reached €357M, with CDMO sales up 38% and gross margin expanding 6.5 percentage points.
See the latest news and media coverage for Rovi. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialized pharmaceutical company researching, manufacturing, and commercializing medicines
rovi.esLast updated
In short: Rovi expanded its U.S. presence by acquiring a Phoenix plant and signed a major manufacturing agreement with Roche for obesity drugs.
Total revenue reached €357M, with CDMO sales up 38% and gross margin expanding 6.5 percentage points.
The deal strengthens Rovi's industrial base in the US and consolidates its position in aseptic filling of sterile injectables.
Operating income reaches 152.5 million euros. CDMO grows 5%, Risperidona ISM® 37%. R&D investment rises 79% to 11.2 million.
Gross margin expands 3.8 points to 62.3%. Heparin sales drop 12%, Okedi rises 37%. Updates 2026 guidance to low-to-mid single-digit growth. Announces plant acquisition completion.
16/11/22 Analyst opinions of the day: ArcelorMittal, Givaudan, Rovi, Scor, Delivery Hero, Infineon, Intesa Sanpaolo, Komax, Symrise, Coltene... 08/11/22 ...
Rovi and Moderna strengthen their alliance in messenger RNA cancer vaccines. Melanoma concentrates the advances and looks to production in...
Rovi also rises, following in the footsteps of its partner Moderna, which has presented preliminary data for its melanoma vaccine; and Ferrovial...
The bullish streak achieved by Rovi in the wake of its earnings release does not prevent JPMorgan from continuing to accelerate its increase in short positions...
Track Rovi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Rovi and other trending companies.